S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.21
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.51
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
OLMA · Olema Pharmaceuticals, Inc.
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
Olema Pharmaceuticals Inc (OLMA)
NASDAQ NMS - GLOBAL MARKET
Biotechnology
$7.03
-0.21
(-2.97%)
● At close: October 21 at 4:00:00 PM EDT
DAY'S RANGE
$7.03
$7.03
$7.47
52-WEEK RANGE
$7.03
$6.48
$36.26
What's happening
- OLMA is down 2.97% today, trading at $7.03. — Live quote
- It's trading within 3% of its 52-week low ($6.48). (Finnhub fundamentals)
- Volume today (69,121) is well below its 3-month average of 1,293,720. (Finnhub fundamentals)
- Reports earnings on 2026-11-10, 19 days away. (Finnhub earnings calendar)
- Last quarter's EPS missed estimates: $-0.61 actual vs. $-0.56 estimated (-9.8%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 6
Buy 10
Hold 2
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (18 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
OLMA
-71.00%
vs S&P 500
-83.78%
1-YEAR RETURN
OLMA
-6.69%
vs S&P 500
-21.25%
6-MONTH RETURN
OLMA
-56.01%
3-MONTH RETURN
OLMA
-37.45%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.61
Est. $-0.56
MISS -9.8%
2026-04-26 (Q1 2026)
$-0.52
Est. $-0.54
BEAT +3.6%
2026-01-26 (Q4 2025)
$-0.50
Est. $-0.54
BEAT +7.3%
2025-10-26 (Q3 2025)
$-0.49
Est. $-0.49
BEAT +0.7%
Valuation Measures & Ratios
Enterprise Value4$588.8M
Forward P/E5—
PEG Ratio6-0.33
Price / Sales (TTM1)—
Price / Book72.54
EV4 / Revenue—
EV4 / EBITDA—
Profit Margin—
Operating Margin—
Return on Equity (ROE8)-48.22%
Return on Assets (ROA9)-43.00%
Avg Volume (3M)1,293,720
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $1.30B | $1.52B | $843.0M | $367.4M | $315.7M |
| P/E | -6.42 | -8.98 | -5.59 | -2.64 | -2.50 |
| Price/Book | 3.02 | 3.17 | 2.74 | 1.06 | 0.82 |
| EV/EBITDA | -5.72 | -7.89 | -4.87 | — | — |
| ROE | -46.98% | -35.27% | -49.09% | -40.29% | -32.94% |
| ROA | -41.57% | -31.94% | -42.83% | -36.42% | -30.83% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short14,696,219
Change from Prior Settlement-8.54%
% of Float—
Days to Cover (Short Ratio)10.19
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Latest SEC filing is Form 8-K, filed 2026-10-15; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Trailing 52-week price return is -6.7%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on OLMA
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Operating income | -$67.2M | -$58.0M | -$45.9M | -$47.9M | -$34.9M | -$37.6M | -$33.5M | -$34.3M |
| Net income | -$63.2M | -$53.1M | -$42.2M | -$43.8M | -$30.4M | -$34.6M | -$30.4M | -$31.0M |
| EPS (diluted) | $-0.61 | $-0.52 | $-0.49 | $-0.51 | $-0.36 | $-0.60 | $-0.54 | $-0.56 |
| EPS (basic) | $-0.61 | $-0.52 | $-0.49 | $-0.51 | $-0.36 | $-0.60 | $-0.54 | $-0.56 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $486.6M | $530.6M | $533.4M | $352.5M | $382.0M | $409.6M | $451.0M | $230.2M |
| Total liabilities | $56.0M | $50.2M | $54.9M | $45.0M | $36.8M | $26.2M | $42.0M | $31.3M |
| Stockholders' equity | $430.6M | $480.5M | $478.6M | $307.5M | $345.2M | $383.5M | $409.0M | $198.9M |
| Total current assets | $469.9M | $513.2M | $515.5M | $334.3M | $367.7M | $396.7M | $438.5M | $218.0M |
| Total current liabilities | $53.0M | $47.2M | $51.8M | $41.7M | $33.2M | $26.1M | $41.8M | $30.7M |
| Cash & equivalents | $48.6M | $52.5M | $48.3M | $35.3M | $52.5M | $50.6M | $139.5M | $35.9M |
| Marketable securities (current) | $412.5M | $452.8M | $457.1M | $293.7M | $309.4M | $342.1M | $294.6M | $178.9M |
| Property, plant & equipment | $382.0K | $356.0K | $274.0K | $486.0K | $560.0K | $653.0K | $746.0K | $849.0K |
| Other non-current assets | — | — | — | — | $15.0K | $14.0K | $15.0K | $15.0K |
| Accounts payable | $1.7M | $3.7M | $9.3M | $3.5M | $934.0K | $151.0K | $4.5M | $2.7M |
| Other current liabilities | $50.7M | $42.5M | $41.4M | $37.0M | $31.1M | $24.9M | $36.1M | $26.9M |
| Common stock & paid-in capital | $8.0K | $8.0K | $8.0K | $7.0K | $7.0K | $7.0K | $7.0K | $4.0K |
| Retained earnings | -$713.8M | -$650.6M | -$597.6M | -$551.5M | -$509.3M | -$465.5M | -$435.1M | -$401.5M |
| Accumulated other comprehensive income (loss) | -$947.0K | -$460.0K | $621.0K | $526.0K | $314.0K | $420.0K | $143.0K | $464.0K |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$45.9M | -$46.0M | -$38.3M | -$34.5M | -$29.9M | -$44.0M | -$26.3M | -$27.0M |
| Investing cash flow | $40.8M | $4.5M | -$162.2M | $17.3M | $34.2M | -$45.1M | -$114.4M | $45.9M |
| Financing cash flow | $1.1M | $45.7M | $213.6M | $41.0K | -$2.5M | $222.0K | $244.3M | $92.0K |
| Free cash flow | -$46.1M | — | — | -$34.5M | -$29.9M | — | -$26.3M | -$27.0M |
| Capital expenditures | $221.0K | — | — | $0 | $0 | — | $0 | $0 |
| Depreciation & amortization | $102.0K | $119.0K | $187.0K | $43.0K | $132.0K | $128.0K | $116.0K | $95.0K |
| Share-based compensation | $12.9M | $10.1M | $4.3M | $4.2M | $4.7M | $4.4M | $6.3M | $5.6M |
| Change in accounts payable | -$1.9M | -$5.7M | $5.8M | $2.4M | $743.0K | -$4.3M | $2.5M | -$1.7M |
| Purchases of investments | $48.2M | $69.9M | $253.4M | $71.7M | $32.9M | $142.9M | $189.2M | $47.5M |
| Tax withholding on stock comp | — | $4.4M | — | — | — | — | — | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating income | -$178.7M | -$142.3M | -$105.0M | -$107.0M | -$71.5M |
| Net income | -$162.5M | -$129.5M | -$96.7M | -$104.8M | -$71.1M |
| EPS (diluted) | $-1.87 | $-2.20 | $-2.14 | $-2.62 | $-1.80 |
| EPS (basic) | $-1.87 | $-2.20 | $-2.14 | $-2.62 | $-1.80 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $533.4M | $451.0M | $276.9M | $215.6M | $295.9M |
| Total liabilities | $54.9M | $42.0M | $23.1M | $18.1M | $11.4M |
| Stockholders' equity | $478.6M | $409.0M | $253.9M | $197.5M | $284.6M |
| Total current assets | $515.5M | $438.5M | $266.5M | $208.9M | $290.7M |
| Total current liabilities | $51.8M | $41.8M | $21.6M | $16.5M | $9.0M |
| Cash & equivalents | $48.3M | $139.5M | $68.5M | $23.7M | $13.8M |
| Marketable securities (current) | $457.1M | $294.6M | $193.3M | $180.7M | $273.4M |
| Property, plant & equipment | $274.0K | $746.0K | $968.0K | $1.5M | $1.5M |
| Other non-current assets | — | $15.0K | — | $2.8M | $540.0K |
| Accounts payable | $9.3M | $4.5M | $2.7M | $374.0K | $23.0K |
| Other current liabilities | $41.4M | $36.1M | $17.9M | $15.2M | $8.1M |
| Common stock & paid-in capital | $8.0K | $7.0K | $4.0K | $3.0K | $3.0K |
| Retained earnings | -$597.6M | -$435.1M | -$305.6M | -$209.0M | -$104.2M |
| Accumulated other comprehensive income (loss) | $621.0K | $143.0K | $347.0K | -$1.8M | -$149.0K |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$146.7M | -$104.4M | -$83.7M | -$82.1M | -$50.7M |
| Investing cash flow | -$155.8M | -$93.5M | -$4.9M | $91.5M | -$275.4M |
| Financing cash flow | $211.3M | $268.8M | $133.4M | $476.0K | $1.4M |
| Free cash flow | — | -$104.5M | — | -$82.4M | -$52.3M |
| Capital expenditures | — | $159.0K | — | $363.0K | $1.6M |
| Depreciation & amortization | $490.0K | $393.0K | $377.0K | $357.0K | $163.0K |
| Share-based compensation | $17.6M | $22.6M | $17.3M | $18.8M | $15.9M |
| Change in accounts payable | $4.6M | $2.5M | $2.3M | $351.0K | -$683.0K |
| Purchases of investments | $500.7M | $395.0M | $255.6M | $213.7M | $487.0M |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding OLMA as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2025-12-26 to 2026-07-24
Recent transactions
- Insiders have net sold 25,000 shares over the last 182 days, across 0 purchases and 2 sales.
- Most recent: Harmon Cyrus (Reporting person) — Open market sale of 12,500 shares on 2026-07-24.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)25,000 sh(2 txns)
Net Shares-25,000
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Harmon Cyrus | Reporting person | Open market sale | 2026-07-24 | 12,500 |
| Mitchell Shawnte | CHIEF LEGAL OFFICER | Option exercise | 2026-03-04 | 25,000 |
| Austin Sasha Lu | VP of Finance and Controller | Grant / award | 2026-02-02 | 11,700 |
| Kovacs Shane William Charles | CH. OPERATING & FINANCIAL OFF. | Open market sale | 2026-01-15 | 100,000 |
| Myles David C. | CH. DISCOV. & NON-CLIN DEV OFF | Option exercise | 2026-01-14 | 50,000 |
| Bohen Sean | President and CEO | Gift | 2025-12-26 | 8,500 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-07-24 | Harmon Cyrus | Reporting person | Open market sale | 12,500 | $11.71 |
| 2026-07-23 | Harmon Cyrus | Reporting person | Open market sale | 12,500 | $11.58 |
| 2026-03-04 | Mitchell Shawnte | CHIEF LEGAL OFFICER | Option exercise | 25,000 | $4.37 |
| 2026-03-04 | Mitchell Shawnte | CHIEF LEGAL OFFICER | Open market sale | 24,767 | $24.25 |
| 2026-03-04 | Mitchell Shawnte | CHIEF LEGAL OFFICER | Open market sale | 233 | $24.69 |
| 2026-03-03 | Mitchell Shawnte | CHIEF LEGAL OFFICER | Option exercise | 15,000 | $4.37 |
| 2026-03-03 | Mitchell Shawnte | CHIEF LEGAL OFFICER | Open market sale | 15,000 | $23.01 |
| 2026-02-02 | Austin Sasha Lu | VP of Finance and Controller | Grant / award | 11,700 | $0.00 |
| 2026-01-20 | Harmon Cyrus | Reporting person | Open market sale | 10,000 | $26.88 |
| 2026-01-15 | Kovacs Shane William Charles | CH. OPERATING & FINANCIAL OFF. | Open market sale | 100,000 | $28.73 |
| 2026-01-14 | Harmon Cyrus | Reporting person | Open market sale | 3,489 | $29.12 |
| 2026-01-14 | Myles David C. | CH. DISCOV. & NON-CLIN DEV OFF | Option exercise | 50,000 | $4.87 |
| 2026-01-14 | Myles David C. | CH. DISCOV. & NON-CLIN DEV OFF | Open market sale | 14,997 | $28.60 |
| 2026-01-14 | Myles David C. | CH. DISCOV. & NON-CLIN DEV OFF | Open market sale | 35,003 | $28.99 |
| 2026-01-13 | Kovacs Shane William Charles | CH. OPERATING & FINANCIAL OFF. | Open market sale | 3,822 | $28.01 |
| 2026-01-13 | Myles David C. | CH. DISCOV. & NON-CLIN DEV OFF | Option exercise | 50,000 | $4.87 |
| 2026-01-13 | Myles David C. | CH. DISCOV. & NON-CLIN DEV OFF | Open market sale | 49,800 | $27.60 |
| 2026-01-13 | Myles David C. | CH. DISCOV. & NON-CLIN DEV OFF | Open market sale | 200 | $28.49 |
| 2026-01-12 | Myles David C. | CH. DISCOV. & NON-CLIN DEV OFF | Open market sale | 10,000 | $28.34 |
| 2025-12-26 | Bohen Sean | President and CEO | Gift | 8,500 | $0.00 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-21 23:37 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-15 | 8-K | 2026-10-12 | View on SEC.gov → |
| 2026-09-02 | 4 | 2026-09-01 | View on SEC.gov → |
| 2026-08-13 | 8-K | 2026-08-13 | View on SEC.gov → |
| 2026-08-10 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-10 | 8-K | 2026-08-10 | View on SEC.gov → |
| 2026-07-27 | 4 | 2026-07-23 | View on SEC.gov → |
| 2026-06-23 | 4 | 2026-06-18 | View on SEC.gov → |
| 2026-06-23 | 4 | 2026-06-18 | View on SEC.gov → |
| 2026-06-23 | 4 | 2026-06-18 | View on SEC.gov → |
| 2026-06-23 | 4 | 2026-06-18 | View on SEC.gov → |
| 2026-06-23 | 4 | 2026-06-18 | View on SEC.gov → |
| 2026-06-23 | 4 | 2026-06-18 | View on SEC.gov → |
Recent news
Headlines about OLMA (Olema Pharmaceuticals, Inc.). Links open the publisher — we don’t host full articles.
-
OLMA Jan 2028 23.000 call (OLMA280121C00023000) stock price, news, quote and history
Yahoo Finance UK · 2026-10-20 -
Olema Pharmaceuticals (NASDAQ:OLMA) Shares Up 7.4% - What's Next?
MarketBeat · 2026-10-19 -
The Zacks Analyst Blog Highlights AstraZeneca, Roche, Puma Biotechnology and Olema Oncology
Yahoo Finance · 2026-10-19 -
Price-Driven Insight from (OLMA) for Rule-Based Strategy
Stock Traders Daily · 2026-10-18 -
Olema Pharmaceuticals, Inc. (OLMA) Stock Price, News, Quote & History
Yahoo! Finance Canada · 2026-10-17 -
Form 13D/A Olema Pharmaceuticals For: 16 October By Investing.com
Investing.com Nigeria · 2026-10-17 -
A 9.99% ownership cap limits warrant exercises at Olema Pharmaceuticals (OLMA).
Stock Titan · 2026-10-16 -
4 Breast Cancer Stocks to Watch During Breast Cancer Awareness Month
Yahoo Finance · 2026-10-16
No headlines in this category right now — try “All”.